Table 2.

Efficacy of T-705 against H5N1 influenza virus infection in mice.

Treatment	Dose (mg/kg/day)	Time of start of therapy (h)	Survivors/total	Day of death (mean ± S.D.)
Expt 1: twice daily for 5 days
0.4% CMC	–	1	0/20	8.2 ± 1.6
T-705	3	1	0/10	7.4 ± 1.1
	10	1	2/10	8.5 ± 2.8
	30	1	8/10**	11.0 ± 4.2
	100	1	10/10**	>21.0*
	300	1	10/10**	>21.0*
Expt 2: every 6 h for 5 days
0.4% CMC	–	72	0/20	7.9 ± 2.7
T-705	300	72	9/10**	7.0
	300	84	10/10**	>21.0*
	300	96	8/9**	7.0
	300	120	3/10*	7.9 ± 2.6

Expt 1: effect of drug dose on survival. Mice were treated twice daily with T-705 or with CMC vehicle for 5 days beginning 1 h after virus exposure. Expt 2: effect of delay in initiation of treatment. Mice were treated with T-705 or with CMC vehicle every 6 h for 5 days, beginning at the indicated hour post-infection. S.D.: standard deviation.

^*P < 0.05.

^**P < 0.001 compared to controls treated with CMC only (Sidwell et al., 2007).